Impact of second-line combination chemotherapy on post-progression survival in metastatic and recurrent pancreatic cancer.

IF 2.8 3区医学 Q3 ONCOLOGY

International Journal of Clinical Oncology Pub Date : 2025-08-01 Epub Date: 2025-06-11 DOI:10.1007/s10147-025-02796-0

Takafumi Mie, Masato Ozaka, Takeshi Okamoto, Tsuyoshi Takeda, Yoichiro Sato, Tatsuki Hirai, Takahiro Ishitsuka, Yuri Maegawa, Takaaki Furukawa, Yukari Suzuki, Takashi Sasaki, Naoki Sasahira

{"title":"Impact of second-line combination chemotherapy on post-progression survival in metastatic and recurrent pancreatic cancer.","authors":"Takafumi Mie, Masato Ozaka, Takeshi Okamoto, Tsuyoshi Takeda, Yoichiro Sato, Tatsuki Hirai, Takahiro Ishitsuka, Yuri Maegawa, Takaaki Furukawa, Yukari Suzuki, Takashi Sasaki, Naoki Sasahira","doi":"10.1007/s10147-025-02796-0","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to evaluate the efficacy of the second-line combination chemotherapy (CC) for patients with metastatic or recurrent pancreatic cancer.Methods: We retrospectively analyzed consecutive patients with metastatic or recurrent pancreatic cancer, who received second-line chemotherapy after disease progression on first-line modified FOLFIRINOX (mFFX) or gemcitabine with nab-paclitaxel (GnP) between January 2014 and March 2023 at our hospital. Overall survival (OS), progression-free survival (PFS), and post-progression survival (PPS) were compared between first-line mFFX and GnP. In addition, OS, PFS, and PPS for second-line treatment with CC and single-agent chemotherapy (SAC) were compared using propensity score matching (PSM).Results: 457 patients (mFFX/GnP: 122/335) were included. Median OS and PPS of mFFX and GnP were 15.5 months vs. 15.0 months (p = 0.73) and 7.7 months vs. 7.2 months (p = 0.37), respectively. After PSM, median OS and median PPS were significantly longer in the CC group than in the SAC group (OS: 16.3 months vs. 12.8 months, p < 0.01; PPS: 8.0 months vs. 5.5 months, p < 0.01). There was no difference in first-line PFS between the two groups (7.1 months vs. 6.4 months, p = 0.74). Performance status at the beginning of first-line treatment, and carbohydrate antigen 19-9 level, Glasgow prognostic score at the end of first-line treatment, and second-line CC were independently associated with OS.Conclusion: Second-line CC achieved longer PPS and OS than SAC. To improve OS, it was important to receive second-line CC.","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1610-1620"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-025-02796-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to evaluate the efficacy of the second-line combination chemotherapy (CC) for patients with metastatic or recurrent pancreatic cancer.

Methods: We retrospectively analyzed consecutive patients with metastatic or recurrent pancreatic cancer, who received second-line chemotherapy after disease progression on first-line modified FOLFIRINOX (mFFX) or gemcitabine with nab-paclitaxel (GnP) between January 2014 and March 2023 at our hospital. Overall survival (OS), progression-free survival (PFS), and post-progression survival (PPS) were compared between first-line mFFX and GnP. In addition, OS, PFS, and PPS for second-line treatment with CC and single-agent chemotherapy (SAC) were compared using propensity score matching (PSM).

Results: 457 patients (mFFX/GnP: 122/335) were included. Median OS and PPS of mFFX and GnP were 15.5 months vs. 15.0 months (p = 0.73) and 7.7 months vs. 7.2 months (p = 0.37), respectively. After PSM, median OS and median PPS were significantly longer in the CC group than in the SAC group (OS: 16.3 months vs. 12.8 months, p < 0.01; PPS: 8.0 months vs. 5.5 months, p < 0.01). There was no difference in first-line PFS between the two groups (7.1 months vs. 6.4 months, p = 0.74). Performance status at the beginning of first-line treatment, and carbohydrate antigen 19-9 level, Glasgow prognostic score at the end of first-line treatment, and second-line CC were independently associated with OS.

Conclusion: Second-line CC achieved longer PPS and OS than SAC. To improve OS, it was important to receive second-line CC.

查看原文本刊更多论文

二线联合化疗对转移性和复发性胰腺癌进展后生存的影响。

背景：本研究旨在评估二线联合化疗（CC）对转移性或复发性胰腺癌患者的疗效。方法：回顾性分析2014年1月至2023年3月在我院连续接受一线改良FOLFIRINOX （mFFX）或吉西他滨联合nab-紫杉醇（GnP）二线化疗的转移性或复发性胰腺癌患者。比较一线mFFX和GnP的总生存期（OS）、无进展生存期（PFS）和进展后生存期（PPS）。此外，使用倾向评分匹配（PSM）比较CC和单药化疗（SAC）二线治疗的OS、PFS和PPS。结果：纳入457例患者（mFFX/GnP: 122/335）。mFFX和GnP的中位OS和PPS分别为15.5个月和15.0个月（p = 0.73）， 7.7个月和7.2个月（p = 0.37）。PSM后，CC组的中位OS和中位PPS明显长于SAC组(OS: 16.3个月vs 12.8个月，p结论：二线CC比SAC获得更长的PPS和OS。为了改善OS，接受二线CC是很重要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Clinical Oncology 医学-肿瘤学

CiteScore

6.80

自引率

3.00%

发文量

175

审稿时长

2 months

期刊介绍： The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.